Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. - Wikidata - wikimedia - TriplyDB

Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.

Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.

http://www.wikidata.org/entity/Q35759060

about

First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques A Comparison of Lower Genital Tract Glycogen and Lactic Acid Levels in Women and Macaques: Implications for HIV and SIV Susceptibility A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections Targeting Trojan Horse leukocytes for HIV prevention.Development of topical microbicides to prevent the sexual transmission of HIV Identification of rhesus macaque genital microbiota by 16S pyrosequencing shows similarities to human bacterial vaginosis: implications for use as an animal model for HIV vaginal infection.Enhanced activity of carbosilane dendrimers against HIV when combined with reverse transcriptase inhibitor drugs: searching for more potent microbicides A guide for standardizing colposcopic observations for the evaluation of topical microbicide products in the pigtailed macaque model.Rectal microbicide development.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model.Pigtailed macaque model refinement: topical microbicide safety in the presence of coitus Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.Gene Expression Profiling of Human Vaginal Cells In Vitro Discriminates Compounds with Pro-Inflammatory and Mucosa-Altering Properties: Novel Biomarkers for Preclinical Testing of HIV Microbicide Candidates.Testing of viscous anti-HIV microbicides using Lactobacillus.Microbicides for HIV prevention.Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.The Effects of Hormones and Vaginal Microflora on the Glycome of the Female Genital Tract: Cervical-Vaginal Fluid UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1 Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.Longitudinal assessment of pigtailed macaque lower genital tract microbiota by pyrosequencing reveals dissimilarity to the genital microbiota of healthy humans Influence of Ethanol as a Co-Solvent in Cyclodextrin Inclusion Complexation: A Molecular Dynamics Study.Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay Pharmacologic opportunities for HIV prevention.Microbicides: still a long road to success Vaginal drug delivery systems for HIV prevention.The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract.RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models.Pharmaceutical development of microbicide drug products.Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.Non-human primate models of hormonal contraception and HIV.Predicting the unpredictable real-world impact of ARV-based microbicides.

P2860

Q21135264-85A40461-3237-4840-ACEF-7D8A158BD7B2 Q27438093-A03462DF-0782-4D16-860B-B61D073C18DE Q29999391-0B13D7AA-F6FC-4B3B-986A-75330A19ADEE Q30369008-2929DB07-E43B-44B0-89E6-3F5493CD0276 Q33518390-F7977E8F-3699-4163-ADB4-0D0405A0452F Q33625073-0D105838-D87A-4220-9B5F-C4B68F1847AA Q33714529-6C688247-A40D-468C-9BB1-5486AB591DE8 Q34005632-5409EA41-02CC-40AA-8A99-A4AD4D3ABD11 Q34392634-0181637E-B49A-4802-81F7-D6C677613272 Q34575590-75841D7B-3DBF-4D2F-AD70-64593BE6A04D Q34737547-9A296B7C-2F88-40AD-B4B1-A41ADB77A4E8 Q34989166-63D6A3C8-CC6D-4A19-A746-646653897C7F Q35083897-F1253A10-B08E-4D72-8650-98EFF539D0D3 Q35563416-382697D6-3E65-4E67-A0AB-EA1C14F85803 Q35619304-3185E780-B4E3-4230-929E-70BC2277865B Q35656128-132463DB-219E-4996-8DE4-F526AEDC6386 Q35734254-8C9B806E-2E1F-43EE-A39E-55C62B7BED8F Q35770899-FA1ACF18-8AF5-49EC-A6EF-8C00790AD950 Q36018776-C0C1B6B2-8F18-4E2E-958A-82F5B6A570AB Q36082673-FC97BB6A-1C3B-4DBA-96ED-C60DD8FB389F Q36086344-F4D901A0-DCD0-4AF4-9BC8-3B4CC60C3022 Q36111516-32BB8EC9-2DEF-4141-A637-A6B2DC74E644 Q36113575-D6F1D475-CCBC-47C8-BA5E-FFC06A7C6A3C Q36250396-1305E6FF-7D36-486E-A3E3-20CA8FA6485A Q36504995-F24662E3-F8C6-4077-BAA1-2D5A8AD15A71 Q36803970-068C6FBC-4453-43BC-B5A2-FA7F76C23095 Q36905431-E51E9655-BF99-4EF3-ADDB-E48A615A7DF7 Q37130757-62EDD2FB-51CE-47FF-826A-BFF76EDDA6FB Q37149107-21FA3226-BE51-4448-B9A1-C8163F55C30A Q37210863-34E3B28B-B925-4F02-B227-DEA83BC4274E Q37428359-7814B21A-BD09-47E7-90D3-D8A26FD28FAA Q37657468-C35F188A-AD60-4D2F-B310-16113A3D8FDD Q37707803-F2976F32-4353-4680-93C1-7F81536C8B69 Q42225882-96336905-1513-44AF-8A10-33938637FE29 Q43233038-6D35508A-E23C-4813-86C1-6B720880158F

P2860

Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.

http://www.wikidata.org/entity/Q35759060

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Preclinical safety assessments ...... ical microbicide formulations.

@ast

Preclinical safety assessments ...... ical microbicide formulations.

@en

type

label

Preclinical safety assessments ...... ical microbicide formulations.

@ast

Preclinical safety assessments ...... ical microbicide formulations.

@en

prefLabel

Preclinical safety assessments ...... ical microbicide formulations.

@ast

Preclinical safety assessments ...... ical microbicide formulations.

@en

P1433

Q35759060-68CE2DA4-EDEF-4D43-8DDA-33CB555A8929

P1476

Q35759060-D21A8499-CC65-422B-B59F-86A9C1331845

P2093

Q35759060-11C5C941-7E22-4B1C-A08E-771E852364D5

Q35759060-36930AF8-D4B6-445E-B632-A3385E7C332C

Q35759060-39E58A5E-0298-4B26-B3BA-93FFECBC23B3

Q35759060-60F544EA-F24C-4C74-9293-ED30543935B8

Q35759060-793F0DCD-84B3-4319-99E7-029EF5B73708

Q35759060-7B45F663-ED1B-4C43-BCF7-1D951A8FE45A

Q35759060-CEE6A780-B4B0-4804-B734-AA5C63646708

P2860

Q35759060-00AA2086-4DB5-493C-93AE-C8601BC2A47F

Q35759060-1ED41E88-A85D-4FD7-8373-2C38461BA147

Q35759060-4930D7A6-3A0F-4659-A3EC-5D47910242E0

Q35759060-580873DD-BFC1-4BC8-BB3F-692620BCD4CE

Q35759060-5A36828C-9695-42C2-8A49-086A9CF2FDD7

Q35759060-85FE2CE4-5289-4173-9AFB-6250782FAC6F

Q35759060-9F37C925-956D-42E2-90AF-AA8E256702F7

Q35759060-AD42E9C6-861B-4468-B23D-EA9A7090865F

Q35759060-D3AC1A57-620A-45D8-B1D0-C4FC6F1ADB0F

Q35759060-D85FB072-8BB6-4682-B177-9AB7FE373805

P304

Q35759060-9236FC40-DA8E-4BF7-A7C9-29477DFEC882

P31

Q35759060-AD79E752-7E2D-4DC2-B4DF-61883F6DACA8

P356

Q35759060-2AB726E5-9CBC-400D-938F-C88D64EDAE4E

P407

Q35759060-16F09E9F-F4B8-40E2-9687-33DEAA09972E

P433

Q35759060-78A007EA-6342-47B9-AD6B-3E693B39502B

P478

Q35759060-111ED99D-29B5-4179-9D08-D483EEB7561C

P577

Q35759060-0AFA70E2-A56F-470A-B387-D48A4832DB62

P5875

Q35759060-586D00DD-1183-42BB-A2E1-940DD18F1CF3

P698

Q35759060-B4CFC8F9-BAE4-4CB8-9338-38B97B855AF4

P932

Q35759060-A459D86C-E29F-4140-B9CD-332AA8D7CD62

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Preclinical safety assessments ...... ical microbicide formulations.

@en

P2093

B J Moncla

http://www.w3.org/2001/XMLSchema#string

D L Patton

http://www.w3.org/2001/XMLSchema#string

J E Balkus

http://www.w3.org/2001/XMLSchema#string

L C Rohan

http://www.w3.org/2001/XMLSchema#string

M A Parniak

http://www.w3.org/2001/XMLSchema#string

S L Hillier

http://www.w3.org/2001/XMLSchema#string

Y T Cosgrove Sweeney

http://www.w3.org/2001/XMLSchema#string

P2860

Microbicides in HIV prevention.

Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.

The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.

A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.

The pig-tailed macaque rectal model: microflora and chlamydial infection.

Effects of nonoxynol-9 on vaginal microflora and chlamydial infection in a monkey model.

Development of vaginal microbicides for the prevention of heterosexual transmission of HIV.

Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

Survival of anaerobes in original specimens transported by overnight mail services.

Topical microbicides. Current status and research considerations for adolescent girls.

P304

1608-1615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00984-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6454330

http://www.w3.org/2001/XMLSchema#string

P698

17353240

http://www.w3.org/2001/XMLSchema#string

P932

1855550

http://www.w3.org/2001/XMLSchema#string